-
NMPA Announcement on Revising the Package Inserts of Sulfasalazine Preparations
2021-01-14
To further protect public medication safety, the NMPA decided to revise the package inserts of Sulfasalazine Preparations. The relevant issues are hereby announced as follows.
-
NMPA Announcement on the Cancellation of Registration Certificates for Phenolphthalein Tablets and Phenolphthalein Buccal Tablets
2021-01-14
The NMPA therefore decided the immediate cessation of production, sales and use of the two drugs in China with their registration certificates (drug approval number) revoked forthright.
-
NMPA Announcement on Issuing the Provisions for the Change Management of Post-approval Drugs (Interim)
2021-01-13
The NMPA organized to formulate of the Provisions for Change Management of Post-approval Drugs (Interim), is hereby promulgated and shall go into effect as of January 12, 2021.
-
NMPA Announcement on Issues Pertaining to Online Application for Drug Registration Affairs
2020-12-28
The NMPA has enabled and officially launched on January 1, 2021 the online application module for drug registration affairs.
-
SAMR Released the Provisions for the Lot Release of Biological Products
2020-12-21
NMPA drafted the Provisions for the Lot Release of Biological Products (hereinafter referred to as the Provisions ).
-
Center for Drug Evaluation of NMPA Announced on Issuing the Administrative Measures for Communication of Drug R&D and Technical Review
2020-12-11
The Center for Drug Evaluation organized the revision of the Administrative Measures for Communication of Drug R&D and Technical Review, been released with NMPA's examination and approval for implementation as from December 10, 2020.
